Venture capital firm Frazier Life Sciences has raised a $1.3 billion fund, the firm’s largest to date and one of the few new biotech investment funds raised amid the ongoing market upheaval.
Just a handful of biotech investors have managed to raise new funds this year. Fundraising is never easy, Frazier general partner Dan Estes told STAT, and this was no exception. However, the firm did manage to surpass its goal and top the $987 million it raised in 2022.
Frazier’s announcement comes at a challenging time for the drug startup sector. Alongside the fundraising drop, investors are also facing existential questions about the future of private biotech investing. Federal funding has been cut back drastically, stifling scientific research that could yield new drug candidates. Interest rates, tariffs, and poor biotech investment returns are also weighing on the industry. All of this has led some VCs to theorize that company creation will subside in the years to come.
